Citius Oncology, Inc. 已成功获得高达3650万美元的融资组合,该笔资金包含债务与股权资本,将专项用于加速其核心产品Lymphir®的商业化布局。此次资本注入有望为公司在肿瘤治疗领域的市场拓展提供强劲动力。
Citius Oncology, Inc. 已成功获得高达3650万美元的融资组合,该笔资金包含债务与股权资本,将专项用于加速其核心产品Lymphir®的商业化布局。此次资本注入有望为公司在肿瘤治疗领域的市场拓展提供强劲动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.